BHARAT BIOTECH INTERNATIONAL LIMITED

Bharat Biotech International has launched Nucelion Therapeutics, a wholly owned CRDMO subsidiary dedicated to cell and gene therapy development and manufacturing from a 30,000 sq ft GMP facility in Genome Valley.

Researchers at the University of Maryland completed a successful Phase 1 trial of a novel trivalent Salmonella conjugate vaccine (TSCV) designed to protect against typhoid fever and invasive non-typhoidal Salmonella infections.

ImmunoACT reported ₹62 crore in revenue and ₹12 crore profit before tax in FY25, marking rare profitability for an Indian biotech startup in its first full year of operations.

Bharat Biotech and GSK announced they will reduce the price of the world's first malaria vaccine RTS,S by more than half to less than $5 per dose by 2028.

Bharat Biotech's oral cholera vaccine Hillchol has demonstrated non-inferiority against both Ogawa and Inaba serotypes in Phase III clinical trials involving 1,800 participants across India.

Biovet, a subsidiary of Bharat Biotech, has launched Biolumpivaxin, the world's first DIVA marker vaccine to protect livestock from Lumpy Skin Disease, which caused over 200,000 cattle deaths in India.

Bharat Biotech has launched India's first integrated Cell and Gene Therapy facility in Hyderabad with a $75 million investment, expanding beyond its core vaccine business into advanced therapeutics.

Biovet, a Bharat Biotech group company, has received CDSCO approval for Biolumpivaxin, the world's first DIVA-marker vaccine for Lumpy Skin Disease in cattle and buffaloes.

FDA approves Ocugen's investigational new drug application for a nasal COVID-19 vaccine, developed at Washington University in St. Louis, advancing to Phase 1 clinical trials this spring.

ICMR is conducting a major clinical trial testing BCG vaccine in vulnerable adult populations, with approximately 100 million people receiving the vaccine as part of the study.